Table 3. Univariate and multivariate analysis of overall survival and progression-free survival in NGH cohort.
|
Overall survival |
Progression-free survival |
|||||
|---|---|---|---|---|---|---|
| |
Univariate analysis |
Multivariate analysis |
Univariate analysis |
Univariate analysis |
||
| Variables | 5-Year survival rate (%) | HR 95% CI P-value | HR 95% CI P-value | 5-year survival rate (%) | HR P-value | HR (95% CI) P-value |
| Age |
|
0.959 |
|
|
1.640 |
|
| ⩽65 years | 46 | 0.513–1.796 | 33 | 0.884–3.042 | ||
| >65 years |
54 |
0.897 |
|
55 |
0.116 |
|
| Sex |
|
2.322 |
1.326 |
|
1.978 |
|
| Male | 44 | 1.284–4.200 | 0.819–2.174 | 40 | 1.130–3.463 | 2.074 (0.857–5.031) |
| Female |
66 |
0.005 |
0.255 |
61 |
0.017 |
0.106 |
| Smoking |
|
1.821 |
0.898 |
|
1.314 |
|
| Yes | 47 | 1.001–3.299 | 0.316–2.359 | 46 | 0.746–2.313 | 1.598 (0.646–3.713) |
| No |
61 |
0.048 |
0.834 |
53 |
0.344 |
0.302 |
| p-Stage |
|
6.605 |
2.677 |
|
9.022 |
|
| I or II | 62 | 2.929–14.89 | 1.394–5.079 | 59 | 4.027–20.21 | 2.935 (1.574–5.420) |
| III or IV |
10 |
<0.001 |
0.004 |
14 |
<0.001 |
<0.001 |
| Histology |
|
1.985 |
1.274 |
|
1.388 |
|
| AC | 57 | 1.047–3.763 | 0.648–2.533 | 51 | 0.768–2.507 | 0.965 (0.509–1.835) |
| Non-AC |
42 |
0.035 |
0.482 |
44 |
0.277 |
0.915 |
| Lymphatic permeation |
|
2.517 |
|
|
2.543 |
|
| Positive | 35 | 1.397–4.534 | 34 | 1.452–4.454 | ||
| Negative |
71 |
0.021 |
|
67 |
0.001 |
|
| Vascular invasion |
|
3.550 |
|
|
2.834 |
|
| Positive | 31 | 1.968–6.405 | 30 | 1.619–4.959 | ||
| Negative |
78 |
<0.001 |
|
70 |
<0.001 |
|
| ASCT2 |
|
3.137 |
|
|
3.183 |
|
| High | 33 | 1.729–5.690 | 2.753 (1.222–7.071) | 30 | 1.814–5.585 | 2.861 (1.324–6.896) |
| Low |
81 |
<0.001 |
0.013 |
78 |
<0.001 |
0.009 |
| CD98 |
|
1.495 |
|
|
1.333 |
|
| High | 47 | 0.832–2.686 | 44 | 0.765–2.325 | ||
| Low |
58 |
0.178 |
|
54 |
0.310 |
|
| Ki-67 |
|
1.887 |
|
|
1.504 |
|
| High | 44 | 1.045–3.407 | 41 | 0.861–2.626 | ||
| Low |
60 |
0.035 |
|
55 |
0.151 |
|
| CD34 |
|
1.379 |
|
|
1.362 |
|
| High | 48 | 0.763–2.492 | 40 | 0.778–2.381 | ||
| Low |
56 |
0.287 |
|
55 |
0.279 |
|
| p-mTOR |
|
1.079 |
|
|
1.168 |
|
| High | 50 | 0.597–1.948 | 46 | 0.663–2.506 | ||
| Low | 53 | 0.802 | 49 | 0.590 | ||
Abbreviations: 95% CI=95% confidence interval; AC=adenocarcinoma; ASCT2=ASC amino-acid transporter 2; CI=confidence interval; HR=hazard ratio; NGH=Nishi-Gunma Hospital; non-AC=non-adenocarcinoma; p-mTOR=phosphorylation of mammalian target of rapamycin; p-stage=pathological stage.
Bold entries show statistically significant difference.